Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

By M. Hidalgo, L. Siu, J. Nemunaitis, J. Rizzo, L. Hammond, C. Takimoto, S. Eckhardt, A. Tolcher, C. Britten, L. Denis and 4 more. Journal of Clinical Oncology, 2001

1,024 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/4b35bea8472aa45c786e81d3bac61b7978a0cdb8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Sliwkowski
2. M. Lacouture

In Oncology

1. M. Sliwkowski
2. M. Lacouture

Citations in the corpus

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023, methodology): “The pharmacokinetics of erlotinib has shown significant variability in previous studies with clearance rates and area under the curve varying up to seven-fold.(33,34) It is possible that escalation of the dose of erlotinib beyond 100 mg in patients not experiencing toxicity may be useful.”
• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005, neutral): “0 lM) [33,34].”
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002, background): “…compete with one of the kinase substrates, ATP, appear to be promising clinically because they exhibit the requisite specificity for EGFR, are orally bioavailable, and have been generally well-tolerated to date in clinical trials (Baselga and Averbuch, 2000; Hidalgo et al., 2001; Woodburn, 1999).”
• Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. (2005, background): “both reversible inhibitors of ErbB1, the most frequently reported AEs were nausea, vomiting, acneiform rash, and diarrhea in patients treated with gefitinib,(33) and diarrhea, rash, nausea, headache, emesis, and fatigue in patients with treated with erlotinib.(34) Dose-limiting toxicities of PKI166,”
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. (2004, background): “A phase I clinical trial of erlotinib has been completed in patients with advanced solid tumors, diarrhea, and cutaneous toxicity were dose-limiting and the recommended dose of erlotinib for phase II evaluation is 150 mg per day on a continuous schedule [15].”